Table SI Baseline Demographic and Clinical Characteristics of patients involved in efficacy analyze

Variables	Patient (n=80)	General group (n=38)	Refractory group (n=38)	P value
Age, year, mean (IQR)	26.0 (18.0, 34.0)	29.0 (18.0，35.5)	24.5 (16.8，32.5)	0.337
Sex, n (%)				
Male	29 (36.2)	14 (36.8)	15 (35.7)	
Female	51 (63.8)	24 (63.2)	27 (64.3)	0.917
BMI, Kg/m^2, mean±SD	21.4 (3.3)	21.0 (2.9)	21.8 (3.6)	0.347
Age of onset, age, mean (IQR)	18.0 (13.0, 31.8)	23.0 (15.0，34.3)	16.0 (10.8, 30.0)	0.025
Duration of disease, month, n (%)				
＜12	16 (20.0)	15 (39.5)	0 (0)	
12~60	32 (40.0)	14 (36.8)	19 (45.2)	
＞60	32 (40.0)	9 (23.7)	23 (54.8)	＜0.001
Current episode duration, month, n (%)				
＜12	34 (42.5)	34 (89.5)	0 (0)	
12~60	34 (42.5)	3 (7.9)	31 (73.8)	
＞60	12 (15.0)	1 (2.6)	11 (26.2)	＜0.001
SALT grade, n (%)				
S1	0 (0)	0 (0)	0 (0)	0 (0)
S2	22 (27.5)	12 (31.6)	10 (23.8)	
S3	27 (33.7)	11 (28.9)	16 (38.1)	
S4	9 (11.3)	5 (13.1)	4 (9.5)	
S5	22 (27.5)	10 (26.4)	12 (28.6)	0.751
Subtype, n (%)				
Alopecia totalis	5 (6.2)	2 (5.3)	3 (7.1)	
Alopecia universalis	17 (21.3)	8 (21.1)	9 (21.4)	
Patch alopecia areata	58 (72.5)	28 (73.6)	30 (71.4)	0.937
Body hair involvement, n (%)				
Eyebrow	39 (48.8)	12 (31.6)	27 (64.3)	0.003
Eyelash	21 (26.3)	6 (15.8)	15 (35.7)	0.043
Body hair	13 (16.3)	5 (13.1)	8 (19.0)	0.476
Nail involvement, n (%)	13 (16.3)	6 (15.8)	7 (16.7)	0.915
Family history, n (%)	10 (12.5)	5 (13.4)	5 (11.9)	0.866
Prior treatment, n (%)				
Topical medication*	69 (86.3)	27 (71.1)	42 (100)	＜0.001
Oral glucocorticoids	53 (66.3)	25 (65.8)	28 (66.7)	0.934
Immunosuppressant**	7 (8.8)	4 (10.5)	3 (7.1)	0.890
Comorbidity, n (%)				
Thyroid disease	8 (10.0)	5 (13.1)	3 (7.1)	0.601
Vitiligo	1 (1.3)	0 (0)	1 (2.4)	1.000
Atopy	9 (11.3)	4 (10.5)	5 (11.9)	1.000

Concomitant therapy, n (%)				
Topical corticosteroids or minoxidil	50 (62.5)	24 (63.2)	26 (61.9)	0.908

BMI, body mass index; SALT, severity of alopecia tool; IQR: interquartile range; SD, Standard Deviation.

*: including topical or intracutaneous injection of glucocorticoid and topical minoxidil

**: including cyclosporine and methotrexate

Table SII. Treatment Outcomes of Tofacitinib in Alopecia Areata patient

SALT grade(n，%)	**Baseline(n=80)**	**3 months(n=80)**	**6months(n=80)**
S0	0(0)	8(10.00)	27(33.75)
S1	0(0)	24(30.00)	36(45)
S2	22(27.50)	24(30.00)	11(13.75)
S3	27(33.70)	18(22.50)	2(2.5)
S4	9(11.30)	3(3.75)	2(2.5)
S5	22(27.50)	3(3.75)	2(2.5)
MH standard statistics	-	6.86	7.75
P value	-	＜0.001	＜0.001

Table SIII. Comparison of Complete Remission rate and Effective rate between refractory group and general group after 6 months of Tofacitinib treatment

	CR	Non-CR	X^2	P value
General group (n=38)	18	20	6.004	0.014
Refractory group (n=42)	9	33		

Table SIV. Comparison of Effective rate between refractory group and general group after 6 months of Tofacitinib treatment

	Effective	Non-effective	X^2	P value
General group (n=38)	38	0	2.068	0.150
Refractory group (n=42)	38	4		

Table SV. Multivariate logistic regression analysis for the Factor Associated with Complete Remission rate After Tofacitinib Therapy

Variable	Univariate Analyses		Multivariable Analyses	
	OR(95%CI)	P	OR(95%CI)	P
Demographic Characteristics				
Age (year)	1.014(0.976, 1.054)	0.469	-	-
Sex, (male/female)	3.641(1.198, 11.066)	**0.023**	5.166(1.337, 19.959)	**0.017**
BMI (kg/m^2)	0.961(0.831, 1.110)	0.586	-	-
Clinical Characteristics				
Age of onset (year)	1.023(0.987, 1.061)	0.206	-	-
Duration of disease(＜ 60months/≥60months)	0.417(0.161, 1.083)	**0.072**	0.536(0.169, 1.701)	0.290
Current episode duration(12months/≥12months)	0.278(0.105, 0.733)	**0.010**	0.813(0.061, 10.910)	0.876
Baseline SALT grade (take S2 as contrast)				
S3	2.667(0.759, 9.368)	0.126	-	-
S4	0.606(0.759, 9.368)	0.467	-	-
S5	3.333(0.663, 16.764)	0.144	-	-
AU or AT	0.661(0.224, 1.946)	0.452	-	-
Eyebrows or eyelashes involvement	0.614(0.240, 1.569)	0.308	-	-
Nails involvement	0.131(0.016, 1.071)	**0.058**	0.077(0.008, 0.741)	**0.026**
Family history	0.821(0.195, 3.466)	0.789	-	-
Comorbidity				
Atopy disease	0.216(0.026, 1.828)	0.160	-	-
Thyroid disease	1.200(0.264, 5.448)	0.813	-	-
Prior treatment				
systemic therapy	1.419(0.539, 3.740)	0.479	-	-
Refractory AA	0.303(0.114,0.803)	**0.016**	0.325(0.023, 4.695)	0.410
Concomitant therapy	1.212(0.4581, 3.210)	0.699	-	-

Values in bold indicate hazard ratios with a $P < 0.10$ in Univariate Analyses and $P < 0.05$ in Multivariable Analyses.
OR: odds ratio; BMI, body mass index; SALT, severity of alopecia tool; AA: alopecia areata; AU: alopecia universalis; AT: alopecia totalis; AE: adverse events.

Table SVI. Adverse events during Tofacitinib treatment.

Adverse events	N (%)
Infection	
Upper respiratory infection	13(10.3)
urinary tract infection	3(2.4)
fungal infection*	3(2.4)
herpes zoster	1(0.8)
Laboratory results**	
Hemoglobin ＜LLN	1(0.8)
AST/ALT 2× ULN	3(2.4)
Dyslipidemia***	10(7.9)
Uric acid ＞ULN	2(1.6)
Creatinine ＞ULN	1(0.8)
Other	
Acne-like rash/acne****	16(12.7)
Seborrheic dermatitis/folliculitis ****	28(22.2)
Paramenia	4(3.2)
Bell palsy	1(0.8)
Gastrointestinal symptoms	1(0.8)
Headache	1(0.8)

* Including one case of tinea capitis, one case of tinea pedis and one case of tinea picularis.

** Patients with abnormal laboratory test results before treatment were not included.

*** Total cholesterol, LDL cholesterol, triglycerides, or lipoprotein (a) levels above the 90th percentile of the general population, or HDL cholesterol levels below the 10th percentile of the general population.

**** Patients who newly develop the disease or have significantly worsened during treatment were included.

ULN, upper limit of normal; LLN, lower limit of normal